Generic Product News (January 2020)

VILAZODONE HYDROCHLORIDE TABLETS

MARKETED BY: Teva

COMPARE TO: Viibryd

The FDA has approved Teva’s vilazodone hydrochloride tablets in 10-, 20-, and 40-mg strengths for the treatment of major depressive disorder. The drug is a selective serotonin reuptake inhibitor approved for use by adults. Initial dosing recommendations are 10 mg orally for 7 days, followed by 20 mg daily for 7 days. Maintenance dosing recommendations are 40 mg orally once a day. Common adverse effects include diarrhea, mild nausea, sleep problems, and vision changes.

FOR MORE INFORMATION: tevapharm.com

IVERMECTIN CREAM, 1%

MARKETED BY: Teva

COMPARE TO: Soolantra Cream, 1%

Teva’s ivermectin topical cream is indicated for the treatment of lesions caused by rosacea, which may affect more than 415 million people worldwide, according to the National Rosacea Society. Ivermectin cream can also be used to treat head lice infestations. Adults should apply the cream to affected areas of the face once a day, but physicians should determine the use and dose for children. Common mild adverse effects (AEs) include a burning sensation and irritation where the cream is applied. More serious AEs may include an allergic reaction or more severe irritation.

FOR MORE INFORMATION: tevapharm.com

MARKETED BY: Dr. Reddy’s Laboratories Ltd

COMPARE TO: Kyprolis

Dr. Reddy’s Laboratories Ltd’s carfilzomib injection, an antineoplastic agent and proteasome inhibitor, has been approved for the treatment of patients with refractory or relapsed multiple myeloma who have received 1 to 3 lines of therapy. Carfilzomib is given in a 28-day treatment cycle by intravenous injection. The drug is extensively and rapidly metabolizing. Common adverse effects include bruising or other signs of low blood cell counts, cough, diarrhea, fever, headache, nausea, swelling in the feet and hands, and tiredness.

FOR MORE INFORMATION: drreddys.com

MARKETED BY: Mylan

COMPARE TO: Emend

Fosaprepitant injection, by Mylan, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. The medication will not treat nausea or vomiting that has already started but is intended as a preventive measure. It works by blocking substance P/neurokinin 1 in the body, which can cause vomiting. Adverse reactions such as flushing, redness, or trouble breathing may occur during treatment, and the infusion may be stopped if this happens.

FOR MORE INFORMATION: mylan.com